Karyotyping along with a 3-probe fluorescence in situ hybridization (FISH) strategy was used to risk stratify therapy in 303 children with B-cell precursor acute lymphoblastic leukaemia. Of the 166 patients risk stratified, karyotype identified 91 (55%). FISH identified all karyotypes accurately, with the exception of hypodiploidy, and risk stratified an additional 75 patients. The frequency of ETV6-RUNX1 is lower and high hyperdiploidy, higher than reported in the west. An adapted 3-probe FISH strategy identified two patients with ETV6-ABL1 fusion who received imatinib. In limited-resource settings, a 3-probe FISH approach provides a practical approach for riskstratified therapy in childhood ALL.
INTRODUCTION

B-cell precursor childhood acute lymphoblastic leukaemia (BCP-ALL)
is characterised by prognostically significant cytogenetic subgroups.
ETV6-RUNX1 fusions and high hyperdiploidy (HeH, 51-67 chromosomes) subgroups, observed in 40-50% of western patients, have cure rates exceeding 90% and are categorised as 'low risk' . 1,2 KMT2A gene rearrangements, intrachromosomal amplification of chromosome 21 (iAMP21) and BCR/ABL1 fusions, seen in ∼10%, identify a 'high-risk' cytogenetic subgroup. The rest occupy the 'intermediate-risk' category. Intensification of therapy, including addition of a tyrosine kinase inhibitor in BCR/ABL1, has improved outcomes in high-risk patients. 3 This pre-treatment cytogenetic risk stratification is a standard component of modern risk-adapted therapy in BCP-ALL. Cytogenetic analysis by karyotyping requires fresh samples, specialist laboratories Abbreviations: BCP-ALL, B-cell precursor acute lymphoblastic leukaemia; FISH, fluorescence in situ hybridization; HeH, high hyperdiploidy; iAMP21, intrachromosomal amplification of chromosome 21; LH/NT, low hypodiploidy/near triploidy and skilled scientists. In limited-resource countries, this is not readily available, resulting in suboptimal risk stratification and suboptimal therapy. Fluorescence in situ hybridization (FISH) testing is rapid, does not require viable cells and is easily learnt. A triple-FISH strategy, with ETV6/RUNX1, BCR/ABL1 fusion probes and a KMT2A breakapart probe, reliably identifies major prognostic cytogenetic subtypes except low hypodiploidy/near triploidy(LH/NT). 4 The ETV6/RUNX1 probe additionally identifies iAMP21 and HeH, as multiple RUNX1 signals in this context signify copy number change in the absence of a fusion. 5, 6 The discrete extra RUNX1 signals here indicate HeH, which is confirmed by FISH analysis using additional centromeric probes in the absence of karyotyping.
This triple FISH strategy has been adopted by the Indian Childhood Collaborative Leukaemia (ICiCLe) group to aid centres without dedicated cytogenetic facilities, as part of the risk stratification strategy to de-intensify therapy in low-risk BCP-ALL.
ABL1 rearrangements other than BCR-ABL1 have been described in BCP-ALL and these cryptic fusions may respond to adjuvant imatinib therapy. 7 Imatinib is widely available in the developing world 
Subsequent sequencing studies confirmed the presence of ETV6-ABL1
fusions in both the patients. Here, we report our experience using 3-probe FISH analysis to therapeutically risk stratify BCP-ALL patients, coupled with an extended cytogenetic strategy to identify other ABL1 fusions.
PATIENTS AND METHODS
Consecutive paediatric patients (age <18 years) diagnosed with BCP-ALL, treated at the Tata Medical Center Kolkata between September 2011 and October 2016, were included in these analyses (n = 303).
Patients were treated after consent on a standardised, risk-stratified, ethics-approved clinical protocol. Conventional karyotype and FISH analyses were performed on bone marrow aspirates using standard protocols as described. 8 To reduce costs, FISH testing was performed as a two-step reflex study. Testing was performed first using the ETV6/RUNX1 dual-colour dual-fusion FISH probe (Abbott, IL). Samples with a negative result for ETV6/RUNX1 fusion were sequentially probed with a BCR/ABL1 dual-colour dual-fusion probe (Abbott) and a KMT2A dual-colour break-apart probe (Abbott), (Figure 1 
RESULTS
Three-probe FISH strategy complements karyotyping
Karyotyping was performed successfully in 252 of 303 BCP-ALL patients (83%), 196 of which were abnormal (Supporting Information Figure S1 ). Karyotyping alone identified prognostically significant subgroups in 91 patients (30%), including HeH in 73, KMT2A rearrangements in seven, BCR/ABL1 in seven and LH/NT in four. classified as intermediate risk (Table 1) . Three-probe FISH strategy serves as a screening tool to detect Ph-negative ABL1-rearranged BCP-ALL.
Extended cytogenetic analysis identified two patients with
ETV6/ABL1 fusions. In both these patients, the BCR/ABL1 fusion probe revealed an additional ABL1 signal, which on metaphase FISH was observed to be on the short arm of chromosome 12 (12p). Metaphase 
DISCUSSION
This study represents a large cohort of systematically cytogenetically characterised paediatric BCP ALL patients from India. 9, 10 Three-probe FISH analysis corroborated and complemented karyotyping, enabling cytogenetic categorisation in 166 of 303 patients (55%). FISH analysis alone additionally identified 25% patients with prognostically relevant cytogenetic subtypes. Hypodiploid ALL is however not detected using the 3-probe FISH strategy. In our setting, this limitation has been addressed by incorporating an inexpensive flow cytometry-based DNA ploidy analysis as part of routine diagnostic immunophenotyping. 11 The study findings are concordant with the reported lower frequency of ETV6/RUNX1 fusion in Indian patients. 9 There was a higher incidence of HeH and thus the overall proportion of standard risk cytogenetics remains similar to those reported in the west.
The frequency of high-risk cytogenetic subtypes (BCR/ABL1, iAMP21, hypodiploidy, and KMT2A-rearranged ALL) is similar to the reported literature.
B-other ALL is a cytogenetically indeterminate group and constitutes nearly 50% of paediatric BCP-ALLs seen at our centre. In this cohort, 3-probe FISH analysis identified two patients with ETV6/ABL1 fusion. In both patients, the detection of an extra ABL1 signal on the short arm of chromosome 12 led us to suspect ETV6/ABL1 fusion.
Since commercial ETV6/ABL1 fusion probes are not available, we further investigated by cohybridising BCR/ABL1 and ETV6/RUNX1 fusion probes on the same metaphase. In one of these patients, an ABL1 break-apart probe was used to confirm ABL1 gene rearrangement.
Where the ABL1 break-apart probe is not available, metaphase FISH analysis using the BCR/ABL1 probe can also detect ABL1 gene rearrangements where the extra ABL1 signal will be observed on a different locus or on a different chromosome.
Contemporary risk-stratified approaches have improved outcomes in BCP-ALL to over 90%. Absence of suitable cost-effective modern diagnostic studies limits risk stratification in resource-constrained settings and contributes to global inequality in outcomes in childhood ALL. 12 Diagnostic approaches using readily available, easily standardised and relatively inexpensive techniques such as the proposed three-probe FISH testing have the potential to successfully address these disparities.
